Biocartis Obtains CE-IVD Mark for MDx Platform, BRAF Mutation Test | GenomeWeb

NEW YORK (GenomeWeb) – Biocartis today announced it has obtained CE-IVD marking for and commercially launched the Idylla molecular diagnostics platform and BRAF Mutation Test.

Idylla is a fully automated real-time PCR system that allows clinicians to perform molecular testing at any time without the need for batching or for trained personnel. It can produce test results in 35 minutes to two hours, enabling same-day results, and its multiplex capability allows for the detection of up to 30 targets with the same sample, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.